Back
Top 7%
17.7%
#1
11.8%
#1
11.8%
Top 1%
9.0%
Top 0.4%
6.0%
Top 21%
5.6%
Top 0.6%
5.0%
Top 82%
5.0%
Top 0.8%
2.8%
Top 9%
1.9%
Top 1%
1.9%
Top 6%
1.6%
Top 39%
1.2%
Top 21%
1.2%
Top 13%
1.0%
Top 11%
0.9%
Top 2%
0.7%
Top 6%
0.7%
Top 17%
0.7%
Top 18%
0.7%
Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England: a matched cohort study in OpenSAFELY-TPP
2024-03-16
primary care research
Title + abstract only
View on medRxiv
Show abstract
IntroductionThe spring 2023 COVID-19 booster vaccination programme in England used both Pfizer BA.4-5 and Sanofi vaccines. All people aged 75 years or over and the clinically vulnerable were eligible to receive a booster dose. Direct comparisons of the effectiveness of these two vaccines in boosting protection against severe COVID-19 events have not been made in trials or observational data. MethodsWith the approval of NHS England, we used the OpenSAFELY-TPP database to compare effectiveness of...
Predicted journal destinations
1
BMJ Open
553 training papers
2
BMJ
49 training papers
3
BMC Medicine
155 training papers
4
Vaccine
140 training papers
5
PLOS Medicine
95 training papers
6
Nature Communications
483 training papers
7
British Journal of General Practice
22 training papers
8
PLOS ONE
1737 training papers
9
New England Journal of Medicine
49 training papers
10
JAMA Network Open
125 training papers
11
The Lancet Infectious Diseases
57 training papers
12
International Journal of Epidemiology
65 training papers
13
eLife
262 training papers
14
Clinical Infectious Diseases
219 training papers
15
Open Forum Infectious Diseases
124 training papers
16
Vaccines
131 training papers
17
The Lancet Regional Health - Europe
32 training papers
18
eClinicalMedicine
55 training papers
19
The Journal of Infectious Diseases
137 training papers
20
Nature Medicine
88 training papers